The Institute of Cancer Research (ICR) is a private-limited-guarant-nsc organization dedicated to advancing cancer research and improving patient outcomes globally. Established in 1954, ICR has been a leading force in understanding and combating this disease for over seven decades. Currently operating under Reg: 00534147, the ICR’s primary focus remains on pioneering scientific discoveries and translating them into tangible benefits for individuals affected by cancer. ICR’s activities encompass a broad spectrum of research, including molecular biology, genomics, immunology, and radiotherapy. The organization conducts fundamental and applied research, utilizing state-of-the-art facilities and a highly skilled team of scientists, clinicians, and technicians. ICR’s work spans multiple disciplines, contributing significantly to the development of novel diagnostic tools, targeted therapies, and preventative strategies. Beyond research, ICR actively engages in clinical trials, supports patient support programs, and collaborates with international partners to facilitate knowledge sharing and accelerate progress in cancer treatment. The ICR’s international presence is significant, with operations and collaborations extending across Europe, North America, and Asia. ICR is a temporary worker, rated A, and operates within the SIC codes of -72190.

The Institute of Cancer Research (ICR) is a private-limited-guarant-nsc organization dedicated to advancing cancer research and improving patient outcomes globally. Established in 1954, ICR has been a leading force in understanding and combating this disease for over seven decades. Currently operating under Reg: 00534147, the ICR’s primary focus remains on pioneering scientific discoveries and translating them into tangible benefits for individuals affected by cancer. ICR’s activities encompass a broad spectrum of research, including molecular biology, genomics, immunology, and radiotherapy. The organization conducts fundamental and applied research, utilizing state-of-the-art facilities and a highly skilled team of scientists, clinicians, and technicians. ICR’s work spans multiple disciplines, contributing significantly to the development of novel diagnostic tools, targeted therapies, and preventative strategies. Beyond research, ICR actively engages in clinical trials, supports patient support programs, and collaborates with international partners to facilitate knowledge sharing and accelerate progress in cancer treatment. The ICR’s international presence is significant, with operations and collaborations extending across Europe, North America, and Asia. ICR is a temporary worker, rated A, and operates within the SIC codes of -72190.